Hookipa halts spending on cytomegalovirus vaccine after seeing phase 2 data

Hookipa Pharma’s hopes of partnering its cytomegalovirus (CMV) vaccine HB-101 have taken a hit, with final phase 2 data showing that giving two doses of the prophylactic prospect was no better at reducing viral infection than placebo in kidney transplant patients.